 in the United States District Court for the District of Massachusetts.){kind=link}
biomodal, an omics-based technology and analytics company, has filed a lawsuit against New England Biolabs (NEB) in the United States District Court for the District of Massachusetts. The lawsuit seeks damages and aims to halt NEB’s production, use, and sale of NEBNext® Enzymatic 5hmC-seq and NEBNext® Enzymatic Methyl-seq products in clinical markets, which biomodal claims infringe on patents it holds exclusively from Boston Children’s Hospital through Children’s Medical Center Corporation (CMCC).
Biomodal, the exclusive licensee of patents invented by Professor Anjana Rao and colleagues, alleges that NEB’s products infringe on key patents related to the use of ten eleven translocation (TET) enzymes and DNA beta-glucosyltransferase (BGT) enzymes in methods to detect methylation and hydroxymethylation. The patents in question include U.S. Patent Nos. 10,337,053 B2; 10,443,091 B2; 10,533,213 B2; 10,731,204 B2; 10,774,373 B2; 10,767,216 B2; 11,072,818 B2; and 11,208,683 B2.
Biomodal’s patented ‘Rao’ technology is central to its duet multiomics solutions, evoC and +modC, which offer advanced genome sequencing capabilities. These solutions integrate genetic and epigenetic information to deliver single-base resolution sequencing data, differentiating between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) on the same DNA molecule. This technology provides a more detailed understanding of the genome, aiding in comprehensive biological insights.
“Biomodal has made significant investments to bring our novel duet platform to market through both our duet evoC and +modC offerings,” stated Peter Fromen, CEO of biomodal. “Built on the pioneering ideas of our Scientific Advisory Board member Anjana Rao and her collaborators, we have developed a comprehensive solution that provides unparalleled insights into the dynamic interplay of genetics and epigenetics. As a company driven by innovation, we are committed to protecting our intellectual property and ensuring our customers can utilize these differentiated solutions to achieve best-in-class results.”
Biomodal’s robust patent portfolio includes over 25 U.S. and 40 international patents, with more than 75 patent applications pending worldwide. The outcome of this lawsuit could have significant implications for the competitive landscape in the genomics and epigenetics sectors.